| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2026―Feb―05 |
Mast cells and histamine receptor-targeted adjunctive treatments for COVID-19: A literature review |
Darrell O. Ricke |
| 2 |
[GO] |
2025―Aug―20 |
Dominant and sustained mutations, deletions, and insertions in the Omicron coronavirus lineages JN.1, KP.3, LB.1, XEC, MC.1, and MV.1 |
Asit Kumar Chakraborty |
| 3 |
[GO] |
2025―Jul―16 |
No new needle in the COVID-19 therapeutic haystack: A COVID-19 therapeutics analysis |
Robert L. Martin |
| 4 |
[GO] |
2024―Sep―06 |
In silico analysis for the proposal of new drugs against the phosphoprotein nucleocapsid of the severe acute respiratory syndrome coronavirus 2 virus |
Amanda Bubula de Souza, Leonardo Pereira de Araújo, Amanda Almeida Morais, Leandro Marcos Santos, Yana Cristina Albanez Santos, Cássia Milene Ribeiro Lopes, et al. (+3) Paulo Vinicius Sanches Daltro de Carvalho, Syed Shah Hassan, Nelson José Freitas da Silveira |
| 5 |
[GO] |
2024―Sep―06 |
Potent and selective inhibitory effect of 4-aminoquinoline derivatives on SARS-CoV-2 replication |
Nicolas Glanzmann, Thamara Kelcya F. Oliveira, Vinicius Carius de Souza, Amanda R. Tucci, Eduarda Alves Penna, Alice Santos Rosa, et al. (+12) Maria Luiza Pereira Baltazar, Matheus José Novais Landim, Vivian Neuza S. Ferreira, Pamella Constantino-Teles, Daniel Dias Countinho Souza, Sylvia Roxo, Caroline Souza de Freitas, Aline de Paula Dias da Silva, Thiago Moreno Lopes Souza, Priscila Vanessa S. Zabala Capriles, Milene Dias Miranda, Adilson D. da Silva |
|
